GLP1R and type 2 diabetes mellitus: Recent guidelines for the management of T2D advocate the use of GLP-1 RAs in various stages of the disease course, such as in patients who are not adequately controlled with metformin, those with established atherosclerotic cardiovascular disease (CV) disease or at high CV risk regardless of the quality of glycemic control, those in whom weight loss is desirable and as the first injectable treatment in patients who do not meet glycemic goals with oral therapies [13].